Cancer Research Journal

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Demographic Profile of Patients with Stage-IV Non-Small Cell Lung Cancer: A Single Center Study in Bangladesh

Background: In Bangladesh, stage IV non-small-cell lung cancer (NSCLC) is the second most common cancer in males among top five most frequent cancers and the increase in lung cancer risk among women reflects changes during the 20th century. Prior conception on the demographic profile of patients with Stage-IV NSCLC may be helpful for the good management of such patients. Aim of the study: The aim of this study was to form the demographic profile of patients with stage IV non-small-cell lung cancer. Methods: This prospective observational study was conducted in National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh during the period from September 2019 to August 2020. A total of 108 patients were enrolled purposively. Detailed history taking thorough physical examination was done along with relevant investigations regarding the demographic and clinical status of the participants. Data were collected by semi structured questionnaire and analysis was done with the help of SPSS version 21.0 and MS Office programs as per need. Results: In this study, almost two third (62%) patients were from <60 years’ age group and the rest 38% were from >60 years’ age group. The mean age was found 56.4±12.2 years and the male-female ratio was 4: 1. More than half (52.8%) of the patients came from poor families, 42 (38.9%) were from middle class and the rest 9 (8.3%) were from high class families. More than one third (36.1%) patients were farmer followed by 31 (28.7%) were businessmen, 25 (23.1%) were service holder and the rest 13 (12.1%) were house wife. Conclusion: As per the findings of this study we can conclude that, male may be major prone to stage IV non-small-cell lung cancer. The frequencies of mid-aged patients of NSCLC are alarming.

Non-Small Cell Lung Cancer, Stage-IV NSCLC, Demographic Profile, Carcinoma

Beauty Saha, Muhammad Rafiqul Islam, Nazma Azim, Salman Bashar Al Aub, Rashedul Islam, et al. (2023). Demographic Profile of Patients with Stage-IV Non-Small Cell Lung Cancer: A Single Center Study in Bangladesh. Cancer Research Journal, 11(3), 112-115.

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Hussain, Syed Md Akram. "Comprehensive update on cancer scenario of Bangladesh." South Asian journal of cancer 2.04 (2013): 279-284.
2. Brzezniak, C., Churinga, J. Thomas, A. (2001) Non-small cell lung can crinite handbook of clinical oncology,5thed. (Abraham J. and Gully J. L., eds), Wolter Kluwer, Market Street, Philadelphia, pp. 26-42.
3. Mohan, A., Latifi, A. N. and Guleria, R., 2016. Increasing incidence of adenocarcinoma lung in India: Following the global trend. Indian journal of cancer, 53 (1), p. 92.
4. Uddin AK, Khan ZJ, Islam J, Mahmud AM. Cancer care scenario in Bangladesh South Asian. J Cancer. 2013; 2: 102-4.
5. Goldstraw, P., et al. "Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol 2007; 2 (8): 706–714 The above article ran in the August 2007 issue without showing the figures on page 711 in color. We regret any inconvenience this may have caused. In this issue, we present Figures 2 and 3 from that article in full color." Journal of Thoracic Oncology 2.10 (2007): 985.
6. Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., Wright, G. M., Melloni, G. and Milano, M. T., 2014. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer. Clinical lung cancer, 15 (5), pp. 346-355.
7. Richard, P. J. and Rengan, R., 2016. Oligometastatic non-small-cell lung cancer: current treatment strategies. Lung Cancer: Targets and Therapy, 7, p. 129.
8. Siegel R, MA J, Zou Z, Jemal A: Cancer statistics. CA Cancer J Clin 2014, 64: 9-29.
9. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK: SEER Cancer Statistics Review: 1975–2008. [].
10. World Medical Association. (‎2001). World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bulletin of the World Health Organization, 79 (‎4) ‎, 373 - 374. World Health Organization.
11. Voigt, Paul, and Axel von dem Bussche. "Enforcement and fines under the GDPR." The EU General Data Protection Regulation (GDPR). Springer, Cham, 2017. 201-217.
12. Aoe, K., Hiraki, A., Ueoka, H., Kiura, K., Tabata, M., Tanaka, M. and Tanimoto, M., 2004. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration, 71 (2), pp. 170-173.
13. Davidov, D., 2014. Thrombocytosis as prognostic factor for survival in patients with advanced non-small cell lung cancer treated with first-line chemotherapy. Journal of IMAB-Annual Proceeding Scientific Papers, 20 (6), pp. 560-564.
14. Maráz, A., Furák, J., Varga, Z., Kahán, Z., Tiszlavicz, L. and Hideghéty, K., 2013. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer research, 33 (4), pp. 1725-1729.
15. Mithoowani H, Febbraro M. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Curr Oncol. 2022 Mar 9; 29 (3): 1828-1839. doi: 10.3390/curroncol29030150. PMID: 35323350; PMCID: PMC8946954.
16. Hoverman JR, Robertson SM: Lung cancer: a cost and outcome study based on physician practice patterns. Dis Manag 2004, 7: 112-123.
17. Davidoff AJ, Tang M, Seal B, Edelman MJ: Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28: 2191-2197.
18. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM: Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008, 14: 297-306.
19. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009, 31: 1069-1081.